Anagenics Navigates Q3 2025 Cash Outflows with $1.79M Loan Facilities
Anagenics Limited reported a cash outflow of $424K for Q3 2025 but maintains robust liquidity with $1.48 million in available funding, supported by a mix of secured and unsecured loans.
- Q3 operating cash outflow of AUD 424,000
- Investing cash outflow of AUD 1.7 million primarily from operational costs
- Financing cash inflow of AUD 321,000 from loan facilities
- Total loan facilities of AUD 1.79 million with AUD 677,000 drawn
- Estimated funding runway of approximately 3.5 quarters at current burn rate
Quarterly Cash Flow Overview
Anagenics Limited has released its Appendix 4C quarterly cash flow report for the period ending 31 March 2025, revealing a net operating cash outflow of AUD 424,000. This outflow reflects ongoing expenditures in research, product development, staff costs, and corporate administration, consistent with the company’s biotech sector profile where upfront investment often precedes revenue generation.
The company’s investing activities also recorded a significant cash outflow of AUD 1.7 million year-to-date, underscoring continued investment in its operational infrastructure and intellectual property, although no new acquisitions or disposals were reported during the quarter.
Financing and Liquidity Position
On the financing front, Anagenics secured AUD 321,000 in cash inflows, primarily from drawdowns on existing loan facilities. The company currently holds unsecured and secured loan facilities totaling AUD 1.79 million, with AUD 677,000 drawn and AUD 1.113 million remaining available. These facilities include a $1 million secured loan from Boom Capital Pty Ltd, backed by a charge over the company’s current and future debtors, and several unsecured short-term loans from private lenders.
Cash and cash equivalents stood at AUD 367,000 at quarter-end, providing a liquidity buffer as the company navigates its cash burn. Combining cash on hand with undrawn loan facilities, Anagenics estimates total available funding of approximately AUD 1.48 million, which translates to an estimated 3.49 quarters of runway at the current operating cash burn rate.
Funding Strategy and Outlook
The company’s detailed disclosure of loan terms reveals a strategic approach to balancing secured and unsecured debt, with interest rates around 10% per annum on the secured facility and interest-free terms on some short-term unsecured loans. The repayment schedules are tied to capital raising events or set maturity dates in late 2025, indicating a reliance on future equity or refinancing to sustain operations.
Notably, Anagenics reported no payments to related parties during the quarter, reflecting a clean governance stance amid its financing activities. The company’s board has authorized the release of this report, affirming compliance with ASX Listing Rule 4.7B and Australian Accounting Standards.
While the report does not provide forward-looking guidance, the disclosed liquidity position and funding runway suggest that Anagenics is managing its cash flow prudently during this phase of operational investment. Market watchers will be keen to see how upcoming capital raising efforts and loan repayments unfold in the coming quarters.
Bottom Line?
Anagenics’ current funding runway offers breathing room, but upcoming capital raises will be critical to sustaining its biotech ambitions.
Questions in the middle?
- What are the company’s plans to improve operating cash flow beyond the current burn rate?
- How will Anagenics manage loan repayments due by the end of 2025 amid ongoing cash outflows?
- Are there any anticipated capital raising events or strategic partnerships in the near term?
